Organ-on-Chip Patents: Who Leads, Where the Gaps Are 2026
Organ-on-Chip Device Engineering Patents
45.8% concentration. The top 5 assignees hold 230 of 502 records in scope, so device-level claim space in this field is unusually consolidated at the top. Filings rose to a peak of 38 in 2020, then eased; the 2021-to-2024 span shows a measured 18% decline (22 to 18), the most recent period that can be read as complete given publication lag. 2025 and 2026 figures will continue to fill in.
- 1THE GENERAL HOSPITAL CORP92
- 2EMULATE INC52
- 3RGT UNIV OF CALIFORNIA38
- 4CALIFORNIA INST OF TECH27
- 5CALIPER LIFE SCIENCES INC21
See the full organ on chip device engineering analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who are the leading patent holders in organ-on-chip device engineering?
One institutional assignee leads with 92 of the 502 records in this landscape, and the top five combined hold 230 records, or 45.8% of the field. The drop-off is steep: fifth place holds 21 records and tenth place holds only 11. This is a leader-plus-long-tail structure rather than an evenly distributed field, so a competitive read should focus first on the top handful of holders rather than the full ranked list.
Is organ-on-chip patent filing still growing?
Filing peaked at 38 records in 2020 and the most recent complete span, 2021 to 2024, shows an 18% decline from 22 to 18 records. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures are still filling in and should not be read as evidence of a further slowdown. The honest read is that pace has cooled from its 2020 peak, not that the field has stalled.
What technology areas get the most patent claims in this space?
Material analysis and testing (IPC class G01N) tags 47.6% of the 502 records, and lab apparatus (B01L) tags 42.0%, with bioreactor and enzyme apparatus (C12M) close behind at 33.9%. Because a single record can carry several IPC classes, these shares add up to more than 100%. MEMS-level microstructural claims (B81B) and catalysis-related processes (B01J) are comparatively thin, each under 6% of records.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Organ on Chip Device Engineering covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.